Literature DB >> 21807867

Combined testing of high-sensitivity troponin T and copeptin on presentation at prespecified cutoffs improves rapid rule-out of non-ST-segment elevation myocardial infarction.

Evangelos Giannitsis1, Tzveta Kehayova, Mehrshad Vafaie, Hugo A Katus.   

Abstract

BACKGROUND: Two recent clinical trials showed that adding copeptin to a conventional cardiac troponin assay improved diagnostic performance for patients with chest pain early after symptom onset. We prospectively tested whether copeptin adds information to that provided by a high-sensitivity cardiac troponin T (hscTnT) assay in the early evaluation of patients with suspected acute myocardial infarction, particularly non-ST-segment elevation myocardial infarction (non-STEMI).
METHODS: We enrolled 503 patients with suspected acute coronary syndrome and onset of chest pain occurring within the previous 12 h. Copeptin was measured on presentation, and hscTnT was measured serially at baseline and after 3 and 6 h. We used ROC curve analysis and likelihood ratio χ² statistics for nested models. Diagnostic sensitivities, specificities, positive predictive values (PPVs), and negative predictive values (NPVs) were calculated for admission values of copeptin alone, hscTnT alone, and the combination of both markers.
RESULTS: For ruling out non-STEMI (after excluding STEMI), an hscTnT concentration <14 ng/L (99th percentile) plus a copeptin concentration <14 pmol/L yielded a diagnostic sensitivity of 97.7% (95% CI, 91.9%-99.7%), an NPV of 99.03% (95% CI, 96.6%-99.9%), a diagnostic specificity of 55.9% (95% CI, 50.6%-61.0%), and a PPV of 34.4% (95% CI, 28.5%-40.7%). ROC curve analysis of the continuous biomarker values on admission demonstrated no added value of using this marker combination for ruling out non-STEMI when hscTnT was used as the standard for diagnosing non-STEMI.
CONCLUSIONS: A strategy using copeptin with hscTnT at prespecified cutoffs improves the ruling out of non-STEMI, compared with using hscTnT alone; thus, this strategy could help to obviate a prolonged stay in the emergency department.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21807867     DOI: 10.1373/clinchem.2010.161265

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  24 in total

1.  Clinical utility of novel biomarkers in acute myocardial infarction.

Authors:  Thomas Stiermaier; Holger Thiele; Ingo Eitel
Journal:  Ann Transl Med       Date:  2016-12

2.  Prognostic value of copeptin in patients with acute myocardial infarction treated with percutaneous coronary intervention: a prospective cohort study.

Authors:  Marta Roczek-Janowska; Michal Kacprzak; Malgorzata Dzieciol; Marzenna Zielinska; Krzysztof Chizynski
Journal:  J Thorac Dis       Date:  2021-07       Impact factor: 2.895

Review 3.  Copeptin as a Diagnostic and Prognostic Biomarker in Cardiovascular Diseases.

Authors:  Danni Mu; Jin Cheng; Ling Qiu; Xinqi Cheng
Journal:  Front Cardiovasc Med       Date:  2022-07-04

4.  Improving the ACS Triage-Using High Sensitivity TroponinI and Copeptin for Early 'Rule-Out' of AMI.

Authors:  M Kankra; A Mehta; J P S Sawhney; S Solanki; S Bhargava; A Ahirwar; A Manocha; P Singla; A Sharma; M Sharma
Journal:  Indian J Clin Biochem       Date:  2022-01-08

5.  Impact of copeptin on diagnosis, risk stratification, and intermediate-term prognosis of acute coronary syndromes.

Authors:  Dariush Afzali; Michael Erren; Hermann-Joseph Pavenstädt; Jörn Ole Vollert; Sabine Hertel; Johannes Waltenberger; Holger Reinecke; Pia Lebiedz
Journal:  Clin Res Cardiol       Date:  2013-05-23       Impact factor: 5.460

6.  Association of high-sensitivity assayed troponin I with cardiovascular phenotypes in the general population: the population-based Gutenberg health study.

Authors:  Christoph Sinning; Till Keller; Tanja Zeller; Francisco Ojeda; Michael Schlüter; Renate Schnabel; Edith Lubos; Christoph Bickel; Karl J Lackner; Patrick Diemert; Thomas Munzel; Stefan Blankenberg; Philipp S Wild
Journal:  Clin Res Cardiol       Date:  2013-11-23       Impact factor: 5.460

Review 7.  Diagnostic accuracy of combined cardiac troponin and copeptin assessment for early rule-out of myocardial infarction: a systematic review and meta-analysis.

Authors:  Tatiana Raskovalova; Raphael Twerenbold; Paul O Collinson; Till Keller; Hélène Bouvaist; Christian Folli; Davide Giavarina; Ulrich Lotze; Kai M Eggers; Anne-Marie Dupuy; Camille Chenevier-Gobeaux; Christophe Meune; Alan Maisel; Christian Mueller; José Labarère
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2013-11-20

Review 8.  The role of copeptin as a diagnostic and prognostic biomarker for risk stratification in the emergency department.

Authors:  Christian H Nickel; Roland Bingisser; Nils G Morgenthaler
Journal:  BMC Med       Date:  2012-01-20       Impact factor: 8.775

9.  Serum copeptin and midregion proadrenomedullin (MR-proADM) after an ultramarathon.

Authors:  Giuseppe Lippi; Federico Schena; Gian Luca Salvagno; Fabian Sanchis-Gomar; Gian Cesare Guidi
Journal:  J Clin Lab Anal       Date:  2014-03-22       Impact factor: 2.352

10.  The combination of high sensitivity troponin T and copeptin facilitates early rule-out of ACS: a prospective observational study.

Authors:  Johan Thelin; Catharina Borna; David Erlinge; Bertil Öhlin
Journal:  BMC Cardiovasc Disord       Date:  2013-06-18       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.